Home  |  Contact

Cellosaurus SW872 (CVCL_1730)

[Text version]

Cell line name SW872
Synonyms SW-872; SW 872
Accession CVCL_1730
Resource Identification Initiative To cite this cell line use: SW872 (RRID:CVCL_1730)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
From: Scott and White Clinic; Temple; USA.
Doubling time: 24 hours (PubMed=16888811).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: SW672; In PubMed=17431109.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=12068308; ATCC).
Homozygous for CDKN2A p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu; c.280_281CC>TT) (ATCC).
Homozygous for PTEN deletion (ATCC).
TP53 p.Ile251Asn (c.752T>A) (PubMed=16888811).
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North2.4
East Asian, South0.14
South Asian1.73
European, North69.64
European, South24.84
Disease Liposarcoma (NCIt: C3194)
Liposarcoma (ORDO: Orphanet_69078)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 36Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP

Penta D9,10
Penta E5,10

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=16888811; DOI=10.1002/jcb.21073
Moneo V., Serelde B.G., Fominaya J., Leal J.F.M., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J., Carnero A.
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
J. Cell. Biochem. 100:339-348(2007)

PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)

PubMed=17426441; DOI=10.4161/cbt.6.4.3816
LaPensee E.W., Reddy S.P., Hugo E.R., Schwemberger S.J., Ben-Jonathan N.
LS14 cells: a model for chemoresistance in liposarcoma.
Cancer Biol. Ther. 6:519-524(2007)

PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729
Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J., Carnero A.
Levels of p27(kip1) determine Aplidin sensitivity.
Mol. Cancer Ther. 6:1310-1316(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22911243; DOI=10.1155/2012/148614
Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S., Munthe E., Myklebost O.
Characterization of liposarcoma cell lines for preclinical and biological studies.
Sarcoma 2012:148614-148614(2012)

PubMed=24726063; DOI=10.1186/1756-9966-33-33
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33-33(2014)

PubMed=24758355; DOI=10.1186/1471-2407-14-281
Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R., Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.
BMC Cancer 14:281-281(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cell line collections ATCC; HTB-92
BCRC; 60432
CLS; 300405/p537_SW-872
NCBI_Iran; C638
Cell line databases/resources CCLE; SW872_SOFT_TISSUE
Cell_Model_Passport; SIDM01159
Cosmic-CLP; 909756
DepMap; ACH-002310
IGRhCellID; SW872
Lonza; 88
Ontologies BTO; BTO:0003743
CLO; CLO_0009201
EFO; EFO_0002373
Biological sample resources BioSample; SAMN03472763
Chemistry resources ChEMBL-Cells; CHEMBL3308837
ChEMBL-Targets; CHEMBL2366302
GDSC; 909756
PharmacoDB; SW872_1547_2019
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM185156
GEO; GSM185157
GEO; GSM482514
GEO; GSM1543668
GEO; GSM1543669
GEO; GSM1670514
Other Wikidata; Q54971215
Polymorphism and mutation databases Cosmic; 684521
Cosmic; 909756
Cosmic; 923383
Cosmic; 2009544
Cosmic; 2307722
Cosmic; 2560246
IARC_TP53; 24518
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number29